ライフサイエンスコーパス: Castleman disease

1 osi sarcoma, body cavity-based lymphoma, and Castleman disease.

2 primary effusion lymphoma, and multicentric Castleman disease.

3 ary effusion lymphoma (PEL) and multicentric Castleman disease.

4 TbetaRII in Kaposi sarcoma and multicentric Castleman disease.

5 primary effusion lymphoma, and some cases of Castleman disease.

6 posi sarcoma, primary effusion lymphoma, and Castleman disease.

7 ry effusion lymphoma (PEL), and multicentric Castleman disease.

8 ry effusion lymphoma (PEL), and multicentric Castleman disease.

9 entation as having localized or multicentric Castleman disease.

10 Castleman disease, an unusual condition of unknown cause

11 herapies successful in the treatment of both Castleman disease and associated autoimmune disease.

12 hieving long-term remission in patients with Castleman disease and associated autoimmune features.

13 This review focuses on the intersection of Castleman disease and autoimmunity with an emphasis on s

14 Multicentric Castleman disease and hemophagocytic syndrome are other

15 Localized and multicentric Castleman disease are different clinical disorders with

16 er primary effusion lymphoma or multicentric Castleman disease B-cell malignancies, and from polyclon

17 Castleman disease can occur in association with autoimmu

18 Castleman disease (CD) in the context of human immunodef

19 Castleman disease (CD) is a lymphoproliferative disorder

20 ganomegaly, potentially including coexisting Castleman disease, endocrinopathy, monoclonal plasma cel

21 ng of pathogenic cell types and cytokines in Castleman disease have allowed the development of target

22 inical types (localized and multicentric) of Castleman disease have been described.

23 Rational approaches to the treatment of Castleman disease have begun to have an impact on diseas

24 ces in understanding the biological basis of Castleman disease have provided new targets for therapeu

25 HIV-associated multicentric Castleman disease (HIV MCD) is a rare lymphoproliferativ

26 ful treatment of HIV-associated multicentric Castleman disease (HIV+MCD) with rituximab-based approac

27 HIV-associated multicentric Castleman disease (HIV-MCD) is a rare lymphoproliferativ

28 HIV-associated multicentric Castleman disease (HIV-MCD) presents with systemic sympt

29 s primary effusion lymphoma and multicentric Castleman disease in AIDS patients.

30 tent lymphadenopathy resembling multicentric Castleman disease in rhesus macaques (RMs) coinfected wi

31 HIV-associated plasmablastic multicentric Castleman disease is an increasingly frequent diagnosis.

32 As the complexity of Castleman disease is more fully understood, additional t

33 oma (KS) herpesvirus-associated multicentric Castleman disease (KSHV-MCD) is a lymphoproliferative di

34 a herpesvirus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is characterized by severe

35 imary effusion lymphoma (PEL), and a form of Castleman disease (KSHV-MCD).

36 et of cells in lytically active multicentric Castleman disease lesions.

37 Localized Castleman disease manifests as either a solitary, well-c

38 Disseminated Castleman disease manifests with diffuse mediastinal lym

39 enesis, both involved in the pathogenesis of Castleman disease, may provide additional unique therape

40 reported as a heralding sign of multicentric Castleman disease (MCD) and other lymphoproliferative di

41 ive agent of two B cell tumors, multicentric Castleman disease (MCD) and primary effusion lymphoma (P

42 recognition of KSHV-associated multicentric Castleman disease (MCD) as a distinct lymphoproliferativ

43 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative disorde

44 Multicentric Castleman disease (MCD) is a lymphoproliferative disorde

45 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative inflamm

46 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphopro

47 HIV-associated multicentric Castleman disease (MCD) is associated with a high risk o

48 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD) patients.

49 gent of Kaposi sarcoma (KS) and multicentric Castleman disease (MCD), a life-threatening, virally ind

50 effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV(+),

51 rimary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and MCD-associated plasmablasti

52 vestigated in patients with KS, multicentric Castleman disease (MCD), and primary effusion lymphoma.

53 lymphoma, and plasma cell-type multicentric Castleman disease (MCD).

54 ary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).

55 ary effusion lymphoma (PEL) and multicentric Castleman disease (MCD).

56 tral/South America), and 2 with multicentric Castleman disease (MCD).

57 ry effusion lymphoma (PEL), and multicentric Castleman disease (MCD).

58 pic (IgMlambda) plasmablasts in multicentric Castleman disease (MCD).

59 been described in some cases of multicentric Castleman disease (MCD).

60 lymphoma (PEL), and a subset of multicentric Castleman disease (MCD).

61 Patients with localized Castleman disease (n = 24) typically had the hyaline-vas

62 Patients with disseminated Castleman disease (n = 6) typically had the plasma cell

63 ional criteria were included: a bone lesion, Castleman disease, organomegaly (or lymphadenopathy), en

64 tuximab in posttrans-plantation multicentric Castleman disease patients and non-neoplastic HHV8-assoc

65 nd at least 1 of the other 3 major criteria (Castleman disease, sclerotic bone lesions, or elevated V

66 Castleman disease was initially described over 50 years

67 n 30 pathologically proved cases of thoracic Castleman disease were reviewed.

68 All patients with Castleman disease who were seen at Texas Medical Center,

69 aposi sarcoma, HHV-8-associated multicentric Castleman disease with microlymphomas and a severe hemop